ALS (Amyotrophic lateral sclerosis)

GPTKB entity

Predicate	Object
gptkbp:instanceOf	neurodegenerative disease motor neuron disease
gptkbp:affects	lower motor neurons motor neurons upper motor neurons
gptkbp:alsoKnownAs	gptkb:Lou_Gehrig's_disease
gptkbp:averageSurvivalAfterDiagnosis	2-5 years
gptkbp:awarenessEvent	gptkb:ALS_Ice_Bucket_Challenge
gptkbp:canBeFamilial	true
gptkbp:canBeSporadic	true
gptkbp:casualties	true
gptkbp:cause	difficulty breathing difficulty speaking difficulty swallowing muscle atrophy muscle weakness
gptkbp:diagnosedBy	gptkb:electromyography_(EMG) MRI clinical examination nerve conduction study
gptkbp:firstDescribed	gptkb:Jean-Martin_Charcot 1869
gptkbp:hasNoCure	true
https://www.w3.org/2000/01/rdf-schema#label	ALS (Amyotrophic lateral sclerosis)
gptkbp:mutationAssociatedWith	gptkb:C9orf72 gptkb:FUS gptkb:SOD1 gptkb:TARDBP
gptkbp:notablePatient	gptkb:Stephen_Hawking gptkb:Lou_Gehrig
gptkbp:percentageFamilialCases	5-10%
gptkbp:percentageSporadicCases	90-95%
gptkbp:prevalence	~2 per 100,000 people
gptkbp:progression	progressive
gptkbp:relatedTo	frontotemporal dementia
gptkbp:riskFactor	gptkb:military age family history male sex
gptkbp:symptom	respiratory failure paralysis spasticity muscle cramps fasciculations
gptkbp:symptomsBeginWith	slurred speech limb weakness
gptkbp:treatment	gptkb:edaravone gptkb:riluzole supportive care
gptkbp:typicalOnsetAge	40-70 years
gptkbp:bfsParent	gptkb:Denny_Scott_Miller gptkb:Dwight_Clark gptkb:Pape_Bouba_Diop gptkb:Philip_Freelon gptkb:Hal_Finney gptkb:Denny_Miller gptkb:Moshe_Levi
gptkbp:bfsLayer	6